

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF
FIRST PATIENT ENROLLMENT FOR INHALED TB BOOSTER IN
INDONESIA

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the Phase I clinical trial for the inhaled tuberculosis vaccine (Adenovirus Type 5 Vector) (“**inhaled TB Booster**”) developed by the Company was officially initiated in Indonesia recently and the first trial patient case of the Phase I clinical trial has been formally enrolled.

Currently, Bacillus Calmette-Guerin is the only available tuberculosis vaccine in the world and is widely vaccinated globally, playing an important role in the prevention of tuberculosis in infants and children. However, the efficacy of Bacillus Calmette-Guerin declines over time and it is unable to enhance vaccine protection through booster dose for vaccination. To address this deficiency, the Company has developed the first generation of a globally innovative tuberculosis booster vaccine (“**TB Booster**”) for the Bacillus Calmette-Guerin-vaccinated population. The Phase Ia and Phase Ib clinical trials for TB Booster were completed in Canada, and the clinical trial data demonstrated its safety and its effectiveness as a Bacillus Calmette-Guerin booster vaccine, as well as its superiority of mucosal immunity.

Based on the accumulation of technology in the development of COVID-19 vaccine for inhalation, the Company has established a complete inhalation pharmacy and quality control system, upgraded the first generation of product, and also increased the antigen components to develop inhaled TB Booster, which is delivered through aerosol inhalation, and it is expected to be able to stimulate the immune response in lungs, so as to clear tuberculosis bacilli and control latent infection, and to achieve the effect of preventing infections.

The Phase I clinical trial was conducted in Indonesia to investigate the safety and immunogenicity of a single dose of inhaled TB Booster in adults aged 18 to 49 years.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, November 13, 2025

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.